TargetBeta
MALT1
MALT1 paracaspase · also PCASP1, MLT · Immunoglobulin like domain containing
3 programs in company-led studies act on MALT1, from 3 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| safimaltibrule | Johnson & Johnson | inhibitor | phase 1 | 41 running | – | NCIt |
| ZE66-0205rule | Eilean Therapeutics | degrader | phase 1 | 11 running | – | the studies' text |
| CARD11-BCL10-MALT1 Complex Inhibitor XL114rule | Dr. Reddy's Laboratories | inhibitor | phase 1 | 20 running | BCL10, CARD11 | NCIt |
Conditions their studies are in
- Leukemia, Lymphocytic, Chronic, B-Cell, 1 program
- Leukemia, Myeloid, Acute, 1 program
- Lymphoma, Mantle-Cell, 1 program
- Lymphoma, Non-Hodgkin, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Aug 15, 2027ZE66-0205 · Eilean Therapeutics · phase 1 · NCT07735728
- Jan 19, 2028safimaltib · Johnson & Johnson · phase 1 · NCT06788509
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.